Aldevron News

In the News: Aldevron Partner, Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has successfully completed the technology transfer of its manufacturing process for the production of REQORSA™ immunogene therapy, the company’s lead drug candidate.

GENPREX-2

 
REQORSA is comprised of TUSC2 plasmid DNA (the active agent in REQORSA) encapsulated in non-viral nanoparticles that are administered intravenously and designed to target tumor cells. Earlier this year, Genprex announced an agreement with Aldevron, LLC to manufacture the TUSC2 plasmid DNA used in REQORSA.
 
To read the full press release, click here.
 
For more information on this partnership, read the original press release here.

Topics: Gene Therapy, Plasmid DNA, Clinical Grade Manufacturing/cGMP, Partnerships